Well with all the food posts to kick off, thought we'd post some news on a potentially promising new diet drug. Bad news is it's not likely to hit the market until 2006 - maybe just a bit late for the holiday season - expect Sanofi-Synthelabo Inc. to begin filing for approvals to market Acomplia in Europe and the United States in the second quarter of 2005, with the drug first becoming available for doctors to prescribe to patients in 2006
Study: Highly Encouraging Two-Year Trial Results Reported for Acomplia
The new diet drug Acomplia (rimonabant) helped people lose significantly more weight than a placebo in a two-year clinical trial, the largest of the studies of this drug conducted to date, according to researchers.
The study also showed that while most of the weight loss occured in the first year, continuing to take Acomplia was important to keeping the weight off. Trial participants who stopped taking the drug after one year regained the weight, while those who stayed on Acomplia kept it off, the researchers said.
Results from the two-year study entitled, Effect of Rimonabant on Weight Reduction and Weight Maintenance: RIO-NORTH AMERICA, were presented on November 9th at the American Heart Association's 2004 Scientific Sessions.
The eagerly awaited study showed that approximately one-third of patients who took a 20 mg dose of Acomplia daily for two years lost in excess of 10 percent of their initial body weight and almost two-thirds of the trial participants lost at least five percent of their body weight.
Equally important, much of the weight loss was of abdominal fat, which is widely viewed as a key indicator of cardiovascular risk.
Waist circumference of trial participants after two years was reduced by 3.1 inches for patients taking a daily 20 mg dose of Acomplia, by 1.9 inches for those taking a lower 5 mg dose, compared to 1.5 inches for trial participants taking a placebo.
Patients taking Acomplia also had significantly improved levels of HDL (good cholesterol) after two years, as well as lower triglycerides and improved insulin sensitivity, according to the researchers.
"I think you're getting a double whammy," said Dr. Xavier Pi-Sunyer, Chief of the Division of Endocrinology at Saint Luke's - Roosevelt Hospital Center in New York. "One is related to the weight loss and the other to the lipid improvement.